These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38317746)

  • 1. Clinical significance of peripheral T-cell receptor repertoire profiling and individualized nomograms in patients with gastrointestinal cancer treated with anti-programmed death 1 antibody.
    Wu J; Yu Y; Zhang S; Zhang P; Yu S; Li W; Wang Y; Li Q; Lu B; Chen L; Luo C; Peng H; Liu T; Cui Y
    Transl Gastroenterol Hepatol; 2024; 9():5. PubMed ID: 38317746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
    Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
    Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.
    Nakahara Y; Matsutani T; Igarashi Y; Matsuo N; Himuro H; Saito H; Yamada K; Murotani K; Hoshino T; Azuma K; Sasada T
    Cancer Immunol Immunother; 2021 Oct; 70(10):2881-2892. PubMed ID: 33751180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor.
    Ji S; Li J; Chang L; Zhao C; Jia R; Tan Z; Liu R; Zhang Y; Li Y; Yin G; Guan Y; Xia X; Yi X; Xu J
    Clin Transl Oncol; 2021 Aug; 23(8):1646-1656. PubMed ID: 33583004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
    Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
    Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy.
    Ma X; Ding Y; Qian J; Wan M; Li N; Mao C; Xiao C; Jiang H; Zheng Y; Wu L; Chen X; Xu N
    Curr Oncol; 2022 Nov; 29(11):8937-8954. PubMed ID: 36421355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TCR Repertoire Diversity of Peripheral PD-1
    Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
    Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma.
    Kato T; Kiyotani K; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya Y; Wang C; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N; Uemura M
    Oncoimmunology; 2021 Jan; 10(1):1862948. PubMed ID: 33537170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients.
    Khunger A; Rytlewski JA; Fields P; Yusko EC; Tarhini AA
    Oncoimmunology; 2019; 8(11):e1652538. PubMed ID: 31646098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
    Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
    PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy.
    Gou M; Qian N; Zhang Y; Wei L; Fan Q; Wang Z; Dai G
    Front Immunol; 2022; 13():950868. PubMed ID: 36225924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
    Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
    Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study.
    Hu F; Peng J; Niu Y; Mao X; Zhao Y; Jiang L
    J Thorac Dis; 2022 Oct; 14(10):4096-4112. PubMed ID: 36389292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.
    Zhang Z; Wang D; Zhang J; Ruan Y; Zhao L; Yang L; Liu Z; Yang L; Lou C
    Cancer Immunol Immunother; 2023 Nov; 72(11):3635-3649. PubMed ID: 37668711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment.
    Liang Z; Huang A; Wang L; Bi J; Kuang B; Xiao Y; Yu D; Hong M; Zhang T
    Aging (Albany NY); 2022 Jan; 14(2):907-922. PubMed ID: 35073519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a nomogram based on stromal score to predict progression-free survival of patients with papillary thyroid carcinoma.
    Tang J; Jiang S; Gao Q; Xi X; Gao L; Zhao R; Lai X; Zhang B; Jiang Y
    Cancer Med; 2021 Aug; 10(16):5488-5498. PubMed ID: 34240816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.
    Lin X; Chen X; Long X; Zeng C; Zhang Z; Fang W; Xu P
    Respir Res; 2023 Feb; 24(1):64. PubMed ID: 36849947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy.
    Abed A; Beasley AB; Reid AL; Law N; Calapre L; Millward M; Lo J; Gray ES
    ESMO Open; 2023 Dec; 8(6):102066. PubMed ID: 37995426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8
    Sheng J; Wang H; Liu X; Deng Y; Yu Y; Xu P; Shou J; Pan H; Li H; Zhou X; Han W; Sun T; Pan H; Fang Y
    Front Mol Biosci; 2021; 8():679130. PubMed ID: 34307450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.